SIRPA and neoplasm: While advancing our understanding of phagocytosis and CD47′s role in solid tumors, further efforts might seek to: (i) maximize CD47-SIRPα disruption, (ii) increase the numbers of phagocytic effector cells [40], and (iii) provide additional pro-phagocytic signals (e.g., another tumor-specific monoclonal antibody, bispecific antibodies, some chemotherapeutics, etc.)that are suppressed by CD47-SIRPα.